Diamond v. Chakrabarty

The Supreme Court of the United States’ decision in Diamond v. Chakrabarty marked a turning point in the field of patent law, particularly concerning biotechnology. For the first time, the Court recognised that a living, human-made microorganism could be patentable subject matter under the patent laws. 

This decision has had a profound impact not only in the United States but across the globe, influencing patent regimes including India’s. 

Background to Diamond v. Chakrabarty Case

Before this case, patent law traditionally excluded living organisms from patentability. The patent statute allowed protection only for “new and useful processes, machines, manufactures, or compositions of matter.” However, courts interpreted this language narrowly to exclude living things, which were seen as discoveries of nature rather than inventions.

Ananda Mohan Chakrabarty, a genetic engineer working for General Electric, developed a bacterium capable of breaking down crude oil, an innovation with potential applications in cleaning oil spills. General Electric filed a patent application for this bacterium, with Chakrabarty named as the inventor. However, the United States Patent Office rejected the application, holding that living organisms did not qualify as patentable subject matter under the existing law.

The rejection was challenged, and the matter eventually reached the United States Supreme Court.

The Legal Question

The Supreme Court in Diamond v. Chakrabarty was tasked with deciding whether a genetically engineered living microorganism falls within the scope of patentable subject matter under Section 101 of the United States Patent Act.

Section 101 allows patents for any new and useful “process, machine, manufacture, or composition of matter.” The controversy centred around whether a living organism, which is naturally occurring but has been modified by human intervention, could be considered a “manufacture” or “composition of matter.”

Diamond v. Chakrabarty Judgement

The Supreme Court in Diamond v. Chakrabarty delivered a narrow majority decision, with Chief Justice Warren E. Burger writing for the five-judge majority.

The majority emphasised that the language of the patent statute was intended to be broad and inclusive. They noted that the terms “manufacture” and “composition of matter” were not confined to inanimate objects, but could encompass living organisms if they were the product of human ingenuity.

The Court distinguished this case from earlier precedents where patents were denied for discoveries of naturally occurring bacteria or other natural phenomena. In Chakrabarty’s case, the bacterium was not merely discovered but was a new organism created by genetic manipulation.

Accordingly, the Court held that a living, human-made microorganism is patentable subject matter because it constitutes a “manufacture” or “composition of matter” under the Patent Act.

The Dissenting View

Four Justices dissented, expressing concern that the Court was extending patent law beyond the clear intent of Congress. The dissenting judges argued that because Congress had not explicitly authorised patents on living organisms, the judiciary should not create such an expansion.

They highlighted that Congress had enacted specific statutes relating to certain plant patents but had not done so broadly for all living organisms. They also raised caution about the broader implications of allowing patents on life forms, including ethical and social concerns.

Impact of the Decision in Diamond v. Chakrabarty

The decision in Diamond v. Chakrabarty is widely recognised as the birth of modern biotechnology patent law. It opened the door for companies and researchers to seek patent protection for genetically modified organisms, which was crucial in attracting investment and fostering innovation.

This ruling also prompted patent offices worldwide to reconsider their stances on patent eligibility of biotechnological inventions.

Indian Patent Law and Biotechnology

India, as a member of the World Trade Organisation and a signatory to the TRIPS Agreement, aligns its patent law with international standards. The Indian Patents Act, 1970, particularly after the 2002 amendments, allows patent protection for microorganisms and biotechnological inventions, subject to certain conditions.

Indian law excludes patents for naturally occurring plants, animals, and biological processes but permits patents for genetically modified microorganisms that demonstrate novelty, inventive step, and industrial applicability.

The reasoning in Diamond v. Chakrabarty resonates in Indian jurisprudence and practice, especially in distinguishing between discoveries (non-patentable) and inventions (patentable).

Conclusion

Diamond v. Chakrabarty remains a seminal case in patent law, firmly establishing that genetically engineered living organisms can be patented. Its influence extends beyond the United States, shaping patent law and biotechnology innovation worldwide, including India. The case illustrates how legal interpretation evolves alongside technological advancements and emphasises the importance of clear legislative frameworks to address emerging challenges in intellectual property.